25/02/2026
Researchers are exploring a promising new urine test that could help detect both pancreatic and prostate cancers by analysing unique cancer-related molecules in urine samples. Pancreatic cancer is often diagnosed at an advanced stage when treatment options are limited and survival rates are low. Prostate cancer is one of the most commonly diagnosed cancers in men and current screening tools can lead to unnecessary invasive procedures. A urine-based approach offers a less invasive option that may signal the presence of these cancers sooner and more comfortably for patients.
The test works by identifying specific biomarkers, proteins or other molecular indicators, that are shed by tumours and appear in urine. Early research suggests that certain combinations of urine biomarkers can distinguish between people with cancer and those without, potentially aiding early detection. Some studies have also shown that urine tests can outperform traditional blood-based markers like PSA for prostate cancer, improving accuracy and reducing unnecessary follow ups for men with benign prostate conditions.
For pancreatic cancer, urinary biomarker panels have shown promise in identifying cases up to a couple of years before traditional diagnosis, offering a possible window for earlier intervention. Combining urine tests with established clinical markers might further enhance detection. While these urine tests are still under development and not yet part of standard care, they represent an active area of research aimed at making cancer screening simpler, less invasive and more precise.
Research Paper 📄
DOI: 10.1016/j.bios.2023.115076